Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer

Head and Neck

Volumn 36, Issue 7, 2014, Pages 976-984

  Strieth, Sebastian ^a   Dunau, Christoph ^b   Michaelis, Uwe ^c   Jäger, Lorenz ^b   Gellrich, Donata ^b   Wollenberg, Barbara ^d   Dellian, Marc ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Munich Biotech AG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

EndoTAG 1; HNSCC; laser Doppler blood flowmetry; Lipopac; vascular disrupting agent

Indexed keywords

CLEMASTINE; DEXAMETHASONE; LIPOSOME; PACLITAXEL; RANITIDINE; ANGIOGENESIS INHIBITOR; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD FLOWMETRY; CANCER FATIGUE; CANCER PAIN; CANCER THERAPY; CHEST TIGHTNESS; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENCAPSULATION; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; LASER DOPPLER FLOWMETRY; LEUKOCYTE COUNT; MALE; MICROVASCULATURE; MOLECULARLY TARGETED THERAPY; NATIONAL HEALTH ORGANIZATION; NAUSEA; OXYGEN SATURATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN METASTASIS; TUMOR VOLUME; XEROSTOMIA; BLOOD; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; HEAD AND NECK NEOPLASMS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SKIN; THROMBOCYTE COUNT; VASCULARIZATION;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, SQUAMOUS CELL; DRUG DELIVERY SYSTEMS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LASER-DOPPLER FLOWMETRY; LEUKOCYTE COUNT; LIPOSOMES; MALE; MIDDLE AGED; PACLITAXEL; PLATELET COUNT; PROSPECTIVE STUDIES; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902550750     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23397     Document Type: Article

References (44)

1. Gold KA, Lee HY, Kim ES,. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009; 115: 922-935.
2. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
3. Bauman JE, Michel LS, Chung CH,. New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol 2012; 24: 235-242.
4. Specenier P, Vermorken JB,. Biologic therapy in head and neck cancer: a road with hurdles. ISRN Oncol 2012; 2012: 163752.
5. Christopoulos A, Ahn SM, Klein JD, Kim S,. Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Head Neck 2011; 33: 1220-1229.
6. Seshadri M, Mazurchuk R, Spernyak JA, Bhattacharya A, Rustum YM, Bellnier DA,. Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia 2006; 8: 534-542.
7. Zhang H, Yun S, Batuwangala TD, et al. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. Int J Cancer 2012; 131: 956-969.
8. Saito K, Khan K, Sosnowski B, Li D, O'Malley BW Jr,. Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy. Laryngoscope 2009; 119: 665-674.
9. Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009; 15: 3484-3494.
10. Denaro N, Russi EG, Colantonio I, Adamo V, Merlano MC,. The role of antiangiogenic agents in the treatment of head and neck cancer. Oncology 2012; 83: 108-116.
11. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT,. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009; 35: 309-321.
12. Krasnici S, Werner A, Eichhorn ME, et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003; 105: 561-567.
13. Kunstfeld R, Wickenhauser G, Michaelis U, et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 2003; 120: 476-482.
14. Campbell RB, Ying B, Kuesters GM, Hemphill R,. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009; 98: 411-429.
15. Strieth S, Dunau C, Kolbow K, et al. Phase I clinical study of vascular targeting fluorescent cationic liposomes in head and neck cancer. Eur Arch Otorhinolaryngol 2013; 270: 1481-1487.
16. Schmitt-Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003; 9: 2335-2341.
17. Eichhorn ME, Luedemann S, Strieth S, et al. Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol Ther 2007; 6: 920-929.
18. Specenier P, Vermorken JB,. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr Opin Oncol 2007; 19: 195-201.
19. Strieth S, Eichhorn ME, Sauer B, et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004; 110: 117-124.
20. Strieth S, Nussbaum CF, Eichhorn ME, et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 2008; 122: 452-460.
21. Strieth S, Eichhorn ME, Werner A, et al. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res 2008; 14: 4603-4611.
22. Bode C, Trojan L, Weiss C, et al. Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep 2009; 22: 321-326.
23. Eichhorn ME, Ischenko I, Luedemann S, et al. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 2010; 126: 1235-1245.
24. Gross N, Ranjbar M, Evers C, et al. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol Vis 2013; 19: 54-61.
25. Fasol U, Frost A, Buchert M, et al. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann Oncol 2012; 23: 1030-1036.
26. Lohr JM, Haas SL, Bechstein WO, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol 2012; 23: 1214-1222.
27. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
28. Sherman AC, Simonton S, Adams DC, Vural E, Owens B, Hanna E,. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Arch Otolaryngol Head Neck Surg 2000; 126: 459-467.
29. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
30. Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P, Fateh-Moghadam A,. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res 1996; 16: 3117-3124.
31. Eichhorn ME, Strieth S, Krasnici S, et al. Protamine enhances uptake of cationic liposomes in angiogenic microvessels. Angiogenesis 2004; 7: 133-141.
32. Creaven PJ, Plager JE, Dupere S, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987; 20: 137-144.
33. Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC,. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 2005; 116: 322-326.
34. Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977; 7: 63-67.
35. Guarneri V, Dieci MV, Conte P,. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother 2012; 13: 395-406.
36. Desai N, Trieu V, Damascelli B, Soon-Shiong P,. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009; 2: 59-64.
37. Adkins D, Ley J, Trinkaus K, et al. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer 2013; 119: 766-773.
38. Ay C, Pabinger I,. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res 2012; 129 Suppl 1: S6-S9.
39. Novak K,. Angiogenesis inhibitors revised and revived at AACR. American Association for Cancer Research. Nat Med 2002; 8: 427.
40. Eichhorn ME, Becker S, Strieth S, et al. Dynamic magnetic resonance tomography for monitoring the efficacy of an anti-vascular tumor therapy by paclitaxel encapsulating cationic lipid complexes. Angiogenesis 2004; 7 (Supp): 18-19.
41. Eichhorn ME, Klotz LV, Luedemann S, et al. Vascular targeting tumor therapy: non-invasive contrast enhanced ultrasound for quantitative assessment of tumor microcirculation. Cancer Biol Ther 2010; 9: 794-802.
42. O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC,. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012; 9: 167-177.
43. Pigott KH, Hill SA, Chaplin DJ, Saunders MI,. Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol 1996; 40: 45-50.
44. Stucker M, Springer C, Paech V, Hermes N, Hoffmann M, Altmeyer P,. Increased laser Doppler flow in skin tumors corresponds to elevated vessel density and reactive hyperemia. Skin Res Technol 2006; 12: 1-6.